PCSK9 and myocardial infarction: Indeed, one small, open-label, 1:1 randomised trial involving 36 participants reported that fc-PCSK9 levels were transiently upregulated following myocardial infarction (MI) and that these levels were significantly reduced with treatment of the PCKS9 inhibitor evolocumab [54].